Immunity Against COVID-19 Vaccine in Healthcare Workers in Argentine

Status Completed

Clinical Trial Summary

Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine.

Clinical Trial Description

Vaccination against coronavirus disease 19 (COVID-19) is an essential primary prevention tool to limit the health and economic effects of the pandemic. The Ministry of Health of the Nation, designed the "Strategic Plan for vaccination", which the first line being the health workers " The National Administration of Medicines, Food and Medical Technology authorized two emergency vaccines for administration, Sputnik V and Sinopharm vaccine. It is important to evaluate immunogenicity and its correlation with the long-term efficacy and safety profile of this vaccines. Objectives: To determine the variation in the levels of Immunoglobulin G (IgG) antibodies in health workers who received a COVID-19 vaccine between the time before the first dose, and after 1 month, 6 months and 12 months after the completion of the immunization, depending on whether they have received the Sputnik V vaccine or the Sinopharm vaccine, and correlate the Immunoglobulin G levels with the presence of adverse events and infection with COVID-19 Methodology: Design: observational and analytical study of a prospective cohort of healthcare workers immunized with some COVID-19 vaccine. The presence of IgG will be determined qualitatively and quantitatively. The immunoglobulin G titer in each period will be compared globally and according to the type of vaccine administered. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04843917
Study type	Observational
Source	Hospital Italiano de Buenos Aires
Contact
Status	Completed
Phase
Start date	April 9, 2021
Completion date	August 9, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04460235` - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma	Phase 4
Recruiting	`NCT04543877` - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study	Early Phase 1
Completed	`NCT00401505` - Rubella Susceptibility in Multiparous Women
Recruiting	`NCT05054621` - Immunogenicity of COVID-19 Vaccine on Heterologous Schedule	Phase 2
Completed	`NCT05083065` - Evaluation of Menstrual Irregularities and Abnormal Uterine Bleeding After Covid-19 Vaccine
Recruiting	`NCT05085145` - Immunogenicity and Safety of COVID-19 Vaccine in People Living With HIV	Phase 4
Completed	`NCT05046548` - This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19	Phase 1/Phase 2
Completed	`NCT01961947` - Study of ASP7374, Cell-culture-derived Influenza Vaccine	Phase 3
Completed	`NCT01961960` - A Study to Evaluate Intramuscular ASP7374	Phase 3
Completed	`NCT00401700` - Influenza Vaccine Postpartum Questionnaire
Completed	`NCT03300050` - Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine	Phase 1
Completed	`NCT01015703` - Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers	Phase 1
Completed	`NCT00560066` - Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions	Phase 4
Active, not recruiting	`NCT05099965` - Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)	Phase 2
Recruiting	`NCT04638985` - Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR	Phase 4
Recruiting	`NCT06136832` - Pneumonia Vaccine Education Intervention Study	N/A
Active, not recruiting	`NCT04741828` - Persistence and Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines in Indonesian	Phase 2/Phase 3
Completed	`NCT05083039` - Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
Completed	`NCT03714737` - Immunogenicity and Safety of Bivalent Meningococcal Serogroups A and C Tetanus Toxoid Conjugate Vaccine in Chinese	Phase 3
Completed	`NCT04664309` - Understanding Immunity to the COVID-19 Vaccines